help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rapoport, B.
Right arrow Articles by Pepitone, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rapoport, B.
Right arrow Articles by Pepitone, M.

Journal of Clinical Endocrinology & Metabolism, Vol 58, 332-338, Copyright © 1984 by Endocrine Society

ARTICLES

Clinical experience with a human thyroid cell bioassay for thyroid- stimulating immunoglobulin

B Rapoport, FS Greenspan, S Filetti and M Pepitone

A sensitive, specific, and practical bioassay for thyroid-stimulating immunoglobulin (TSI) is now available for clinical use. Fifty-seven of 61 patients with untreated hyperthyroid Graves' disease were TSI positive (sensitivity, 93%). TSI was undetectable in all normal subjects and in patients with Hashimoto's thyroiditis (without concurrent Graves' ophthalmopathy), nontoxic goiter, and toxic nodular goiter (specificity, 100%). The prevalence of TSI in serum declined after therapy, particularly during methimazole or propylthiouracil treatment. TSI correlated well with relapse or remission after antithyroid drug therapy. All 12 patients who were TSI negative at the time of discontinuing antithyroid drug therapy remained in remission (average follow-up of 10 months). TSI values in Graves' disease correlated better with thyroid dysfunction than with ophthalmopathy. Prenatal TSI activity tended to be higher in mothers of infants who developed neonatal Graves' disease than in at-risk mothers who delivered normal infants. However, there was considerable overlap between the two groups.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
C.-R. Chen, G. D. Chazenbalk, K. A. Wawrowsky, S. M. McLachlan, and B. Rapoport
Evidence that Human Thyroid Cells Express Uncleaved, Single-Chain Thyrotropin Receptors on Their Surface
Endocrinology, June 1, 2006; 147(6): 3107 - 3113.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Costagliola, N. G. Morgenthaler, R. Hoermann, K. Badenhoop, J. Struck, D. Freitag, S. Poertl, W. Weglöhner, J. M. Hollidt, B. Quadbeck, et al.
Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves' Disease
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 90 - 97.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. W. C. Kung and B. M. Jones
A Change from Stimulatory to Blocking Antibody Activity in Graves' Disease during Pregnancy
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 514 - 518.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kakinuma, G. D. Chazenbalk, J. C. Jaume, B. Rapoport, and S. M. McLachlan
The Human Thyrotropin (TSH) Receptor in a TSH Binding Inhibition Assay for TSH Receptor Autoantibodies
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2129 - 2134.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society